Results 101 to 110 of about 1,844 (180)

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review

Journal of Cardiovascular Development and Disease
Hypertrophic cardiomyopathy (HCM) is characterized by excessive growth of myocardial tissue, most commonly due to genetic mutations in sarcomere proteins.
Randeep Gill, Arsalan Siddiqui, Brianna Yee, Michael V. DiCaro, Nazanin Houshmand, Tahir Tak   +5 more
doaj   +1 more source

Recent Advances in Novel Modulators for Cardiac Myosin Disorders

Pharmaceutical Fronts
In advanced stages of heart disease, most cases are characterized by heart failure, where the heart's systolic and diastolic functions are weakened, and then it cannot meet the body's normal oxygen demands.
Hancheng Wang, Mengfei Wang, Bo Han, Qiushi Chen, Qingwei Zhang   +4 more
doaj   +1 more source

Increasing Cardiac Myosin Super-Relaxation With Decreasing Metabolic Demand [PDF]

I schemic heart disease often leads to heart failure with reduced ejection fraction and to a puzzling condition termed hibernating myocardium, where the left ventricle is dysfunctional but still viable.1 Strikingly, the hibernating myocardium experiences
Galán-Arriola, Carlos, Ibanez, Borja, Ochala, Julien, Veiberg, Vebjørn   +3 more
core   +1 more source

Diagnostic Challenges and Management of Hypertrophic Cardiomyopathy with Left Ventricular Outflow Tract Obstruction in a Patient with Hypertension

Folia Cardiologica
Hypertrophic cardiomyopathy (HCM) is characterized by the presence of left ventricular hypertrophy (LVH) that cannot be explained by atypical loading conditions.
Nina Marta Kubikowska, Martyna Świerkowska, Robert Antoniak, Krzysztof Ozierański, Aleksandra Gąsecka   +4 more
doaj   +1 more source

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri   +13 more
doaj   +1 more source

Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle [PDF]

, 2021
Coppini, R., Dente, M., Ferrantini, C., Pioner, J. M., Piroddi, N., Poggesi, C., Scellini, B., Tesi, C., Vitale, G.   +8 more
core   +1 more source

Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target [PDF]

Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disease marked by abnormal ventricular hypertrophy. Recent studies have highlighted that left atrial (LA) remodelling—including dilation, fibrosis, and functional impairment ...
Cameli, Matteo, D'Ascenzi, Flavio, Olivotto, Iacopo, Petrone, Alessio, Piazzai, Chiara, Stefanini, Andrea   +5 more
core   +1 more source

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside [PDF]

, 2022
Coppini, Raffaele, Olivotto, Iacopo, Palandri, Chiara, Santini, Lorenzo   +3 more
core   +1 more source

Correction to: Mavacamten: First Approval

Drugs, 2022
openaire   +1 more source

Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond [PDF]

, 2022
Olivotto, Iacopo
core   +1 more source